61 results about "Cerebral arterial spasm" patented technology

The present invention provides novel polypeptides comprising heat shock protein 20 (HSP20)-derived polypeptides to treat or inhibit smooth muscle vasospasm, as well to treat and inhibit smooth muscle cell proliferation and migration.

The present invention relates to devices and systems that alter intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform by oscillating the contraction and expansion of a compressible composition within the cranial or spinal cavities such that they increase intracranial capacity. The contraction and expansion of the compressible composition in the oscillating compliance devices can be due to an individual's intracranial pressure, the result of the expansion and compression of a reservoir which is mediated by the contractility of the heart or driven by a pump gaited to a biorhythm. The invention also relates to methods for protecting an individual's brain from abnormal arterial pulsations and for altering an individual's cerebral blood flow using the devices and systems of the invention. The oscillating compliance devices can be used to treat several diseases and / or conditions characterized by altered / abnormal intracranial compliance, cerebral blood flow and / or intracranial pressure pulsatility / waveform, including hydrocephalus, stroke, dementia and migraine headaches, vasospasms, congestive heart failure, cardiopulmonary bypass or carotid endarterectomy.

A delivery system for sustained release of a calcium-channel blocking agent is adapted for introduction in the cerebrospinal fluid of a subject. The delivery system comprises a solid dispersion product of a calcium-channel blocking agent in a mixture of a (i) first poly(lactide-co-glycolide) having a molecular weight distribution centered around a first number average molecular weight Mn1 and a (ii) second poly(lactide-co-glycolide) having a molecular weight distribution centered around a second number average molecular weight Mn2, wherein Mn1 is in the range of from 2000 to 3000 g / mol and the ratio of Mn1 / Mn2 is from 1.8 to 3.5. The delivery system is deposited in the vicinity of or adjacent to a blood vessel showing vasospasm or suspected of developing vasospasm.

Novel polymorphic forms of bosentan and processes for their preparation are disclosed. Further, pharmaceutical compositions comprising said polymorphic forms and the use of said compositions in the treatment of patients suffering from endothelin receptor mediated disorders, for example, cardiovascular disorders such as hypertension, pulmonary hypertension, ischemia, vasospasm and angina pectoris are disclosed.

A device and method for treatment of intracranial vasospasm is provided. The device is a microcatheter having a steeply tapered end and is thicker walled, and in a preferred embodiment is braided to provide greater pushability. In order to achieve a thicker walled catheter, in one embodiment, the inner lumen diameter can be reduced, leaving the outer diameter the same while in another embodiment the catheter is larger in outer diameter. In one embodiment, the microcatheter is coated with performance enhancing lubricant, such as a hydrophilic coating. Further, the microcatheter can also be coated with drugs and serve as a drug delivery device, drugs being embedded into vessel intima. In the use of the method of treatment, the device is fed into the smaller arterial vessels in the brain simultaneously dilating arteries of various caliber along the path of the catheter to relieve vasospasm; pharmacological agents can then be delivered by the microcatheter to further effect treatment.